Pfizer, Inc. (NYSE:PFE) Q3 2024 Earnings Conference Call October 29, 2024 10:00 AM ET
Company Participants
Francesca DeMartino - Chief Investor Relations Officer & SVP
Albert Bourla - Chairman & CEO
Dave Denton - CFO
Mikael Dolsten - Chief Scientific Officer and President of Research & Development
Chris Boshoff - EVP & Chief Oncology Officer
Alexandre de Germay - EVP & Chief International Commercial Officer
Conference Call Participants
Chris Shibutani - Goldman Sachs
Kripa Devarakonda - Truist
Umer Raffat - Evercore
Trung Huynh - UBS
Louise Chen - Cantor
Geoff Meacham - Citi
Terence Flynn - Morgan Stanley
Evan Seigerman - BMO Capital Markets
Courtney Breen - Bernstein
Steve Scala - TD Cowen
Rajesh Kumar - HSBC
Akash Tewari - Jefferies
Vamil Divan - Guggenheim Securities
Dave Risinger - Leerink Partners
Chris Schott - JPMorgan
Mohit Bansal - Wells Fargo
Operator
Good day, everyone, and welcome to Pfizer's Third Quarter 2024 Earnings Conference Call. Today's call is being recorded. At this time, I would like to turn the call over to Francesca DeMartino, Chief Investor Relations Officer and Senior Vice President. Please go ahead, ma'am.
Francesca DeMartino
Good morning, and welcome to Pfizer's earnings call. I'm Francesca DeMartino, Chief Investor Relations Officer. On behalf of the Pfizer team, thank you for joining us. This call is being made available via audio webcast at pfizer.com. Earlier this morning, we released our results for the third quarter of 2024 via a press release that is available on our website at pfizer.com.
I'm joined today by Dr. Albert Bourla, our Chairman and CEO; and Dave Denton, our CFO. Albert and Dave have some prepared remarks, and we will then open the call for questions. Members of our leadership team will be available for the Q&A session, including Dr. Andrew Baum, who recently joined Pfizer as EVP and Chief Strategy and Innovation Officer.
Before we get started, I want to remind you that we will be making forward-looking statements and discussing certain non-GAAP financial measures. I encourage you to read the disclaimers in our slide presentation, the press release we issued this morning and the disclosures in our SEC filings, which are all available on the IR website on pfizer.com. Forward-looking statements on the call are subject to substantial risks and uncertainties, speak only as of the call's original date, and we undertake no obligation to update or revise any of the statements.
With that, I will turn the call over to Albert.